Pfizer takes pipeline blow as it abandons cardiomyopathy dru...

Pfizer has stopped development of a drug to treat cardiomyopathy caused by a rare form of heart disease, after it proved ineffective in a phase 3 trial.

Array, Pierre Fabre bowel cancer therapy ‘could replace chem...

As Lyrica patent expiry looms, Pfizer buys Array for $11.4bn

Pfizer has a made a $48 per share play for Array Biopharma, which values the cancer specialist at $11.4 billion.

Does NEMO bring us a step closer in the fight against melano...